Sanofi and Regeneron expand antibody alliance in deal worth up to $8bn

Sanofi and Regeneron Pharmaceuticals, Inc. are expanding their long-running antibody collaboration through an agreement that could generate up to $8 billion in payments, adding four next-generation long-acting immunology antibodies to their joint development portfolio.

Under the expanded agreement, Regeneron will receive $1 billion upfront from Sanofi and could receive up to a further $7 billion in development, regulatory and commercial milestones. The companies will share development and commercialisation costs and divide future profits from the new programmes equally on a global basis.

The agreement extends a collaboration that dates back more than 20 years and has produced Dupixent (dupilumab), one of the world’s most widely used antibody medicines. More than 1.5 million people are currently receiving Dupixent across nine indications, according to the companies.

Four long-acting antibodies added to the alliance

The expanded Sanofi Regeneron antibody alliance covers four Regeneron-invented programmes targeting pathways associated with type 2 inflammation.

The portfolio includes an interleukin-13 (IL-13) antibody, an IL-4xIL-13 bispecific antibody, an interleukin-4 (IL-4) antibody and an interleukin-4 receptor alpha (IL-4Rα) antibody.

One of the programmes, REGN20423, is already in clinical development. The long-acting IL-13 monoclonal antibody is being evaluated in a Phase 1 clinical study for atopic dermatitis.

The remaining three antibodies are expected to enter clinical studies in 2027, giving the expanded collaboration a mixture of clinical-stage and preclinical programmes.

Regeneron will lead research and development activities under the agreement, while Sanofi will lead global commercial efforts. The companies will share development and commercialisation costs and future profits equally.

Sanofi strengthens its next-generation immunology pipeline

The deal gives Sanofi access to a broader group of Regeneron-originated antibody programmes while retaining the commercial role that has helped establish the existing immunology franchise.

Sanofi’s Chief Executive Officer Belén Garijo described the agreement as a step towards strengthening the company’s innovation pipeline and developing the next generation of therapies for immune-mediated diseases.

For Regeneron, the arrangement provides additional financial and commercial resources for advancing its antibody programmes while maintaining a 50:50 economic structure for the new products.

The companies have also settled their previous collaboration-related litigation, removing a legal dispute from the expanded relationship. Reuters described the agreement as a reset of the previously strained partnership.

Dupixent provides the commercial foundation

The expanded alliance builds on the success of Dupixent, which targets the signalling pathways of IL-4 and IL-13 and was developed using Regeneron’s VelocImmune technology.

Dupixent has regulatory approvals in more than 60 countries across multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria and chronic obstructive pulmonary disease, among others.

The existing profit-sharing arrangement for Dupixent will remain unchanged under the new agreement.

The companies are therefore using a different economic structure for the new programmes while preserving the existing commercial framework around their established product.

Lunsekimig could expand the collaboration further

The agreement also provides Regeneron with an option to include Sanofi’s lunsekimig in the collaboration.

Lunsekimig is an investigational bispecific Nanobody VHH therapy targeting TSLP and IL-13. The option can be exercised after completion of its Phase 3 studies in chronic obstructive pulmonary disease.

This provision could broaden the scope of the alliance beyond the four Regeneron-originated antibodies, although any inclusion of lunsekimig remains conditional on the specified development milestone.

What the Sanofi Regeneron deal means for the pharmaceutical sector

The agreement represents a significant commitment to antibody-based immunology development at a time when pharmaceutical companies are seeking to extend established franchises and build new sources of growth.

For Sanofi, the partnership provides access to additional Regeneron antibody programmes while leveraging the companies’ existing scientific and commercial relationship.

For Regeneron, the deal brings $1 billion in upfront funding and the possibility of another $7 billion in milestone payments, while sharing the cost and commercial risk of taking the programmes through development and potential launch.

The structure also links Regeneron’s research capabilities with Sanofi’s global commercial infrastructure. That combination was central to the development and expansion of Dupixent and is now being applied to a new group of long-acting immunology candidates.

The commercial opportunity remains dependent on clinical development, regulatory approval and eventual market uptake. Three of the four newly added antibodies have yet to enter clinical studies.

What to watch next

The next important milestones will be the progression of REGN20423 through its Phase 1 programme and the expected entry of the other three antibodies into clinical studies in 2027.

The potential addition of lunsekimig will also depend on the outcome and completion of its Phase 3 COPD studies.

For the wider pharmaceutical industry, the development of these programmes will provide an indication of whether the Sanofi–Regeneron model can reproduce the commercial and clinical impact achieved with Dupixent across a new generation of immunology therapies.

Market Signal: The expanded alliance points to a broader pharmaceutical strategy in which established blockbuster collaborations are being used as platforms for developing and commercialising follow-on antibody therapies. The evidence currently supports the strategic significance of the deal, but the commercial outcome of the new programmes remains dependent on clinical and regulatory progress.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates.